Revive Therapeutics AI Stock Analysis
Want to see TSE:RVV full AI Analyst Report?
Revive Therapeutics (RVV) AI Stock Analysis
Revive Therapeutics
(CNQX:RVV)
The score is driven primarily by severely distressed financials, including no revenue, negative equity, ongoing losses, and cash burn. Bearish technical positioning and the absence of meaningful valuation support reinforce the very high-risk profile.
Revive Therapeutics (RVV) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 4.45M
- Dividend Yield
- ―
- Average Volume (3M)
- 154.00K
- Price to Earnings (P/E)
- -12.5
- Beta (1Y)
- -2.06
- Revenue Growth
- ―
- EPS Growth
- 90.84%
- Country
- Canada
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Revive Therapeutics Business Overview & Revenue Model
Company Description
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory...
Revive Therapeutics Financial Statement Overview
Summary
Highly distressed financial profile: zero revenue, persistent operating and net losses, deeply negative equity, and continued negative operating and free cash flow. Debt elimination and reduced losses provide limited offset.
Income Statement
1Very NegativeBalance Sheet
4Very NegativeCash Flow
12Very Negative| Breakdown | TTM | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -189 | -189 | -248 | -328 | -434 | -578 |
| EBITDA | -1.05M | -1.05M | -11.01M | -5.60M | -5.52M | -17.74M |
| Net Income | -1.02M | -1.02M | -11.01M | -5.62M | -6.32M | -17.83M |
Balance Sheet | ||||||
| Total Assets | 283.38K | 283.38K | 205.02K | 10.64M | 14.25M | 17.07M |
| Cash, Cash Equivalents and Short-Term Investments | 14.83K | 14.83K | 24.56K | 773.07K | 2.09M | 3.92M |
| Total Debt | 0 | 0 | 66.87K | 25.22K | 219.69K | 327.73K |
| Total Liabilities | 4.30M | 4.30M | 3.66M | 3.40M | 3.60M | 4.46M |
| Stockholders Equity | -4.02M | -4.02M | -3.46M | 7.23M | 10.65M | 12.60M |
Cash Flow | ||||||
| Free Cash Flow | -158.53K | -158.53K | -807.66K | -3.29M | -6.03M | -13.06M |
| Operating Cash Flow | -158.53K | -158.53K | -807.66K | -3.29M | -6.03M | -13.06M |
| Investing Cash Flow | 0 | 0 | -30.00K | 0 | 0 | 0 |
| Financing Cash Flow | 148.80K | 148.80K | 39.15K | 1.98M | 4.20M | 376.35K |
Revive Therapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RVV, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RVV.
Revive Therapeutics Peers Comparison
Overall Rating
TSE:RAMM42Neutral
TSE:PCLO39Underperform
TSE:RVV39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | CAD 1.79M | -0.20 | -194.41% | ― | -66.40% | 31.38% | |
| 39Underperform | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% | |
| 39Underperform | CAD 6.67M | -12.50 | 26.78% | ― | ― | 90.84% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:RVV | Revive Therapeutics | 0.01 | 0.00 | 50.00% | |
| TSE:PCLO | Pharmacielo | 0.04 | 0.00 | 0.00% | |
| TSE:RAMM | Ramm Pharma Corp | 0.01 | -0.04 | -75.00% |
Revive Therapeutics Corporate Events
Revive Therapeutics Moves to Build Global Bucillamine Franchise in Biodefence and Rare Diseases
PositiveRevive Therapeutics outlined a strategy to transform bucillamine into a globally protected therapeutic franchise spanning medical countermeasures, orphan diseases and government preparedness programs. The plan focuses on strengthening patent protecti...
Revive Therapeutics Moves to Settle Trade Debt Through Share Issuance
NeutralRevive Therapeutics has proposed a shares-for-debt settlement under which it plans to issue up to 1,221,516 common shares at a deemed price of $0.05 to extinguish $61,061 in outstanding trade payables owed to two arm’s length creditors. The transacti...
Revive Therapeutics Sets Bucillamine-Led Strategy for Biodefence and Pandemic Countermeasures
PositiveRevive Therapeutics has outlined a strategy to build a focused portfolio of medical countermeasures for biodefence and pandemic preparedness, anchored by its drug candidate bucillamine. The plan aims to serve government and public-health buyers who r...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 01, 2026
